CY1119914T1 - Νεο αντι-ανθρωπινο ngf αντισωμα - Google Patents

Νεο αντι-ανθρωπινο ngf αντισωμα

Info

Publication number
CY1119914T1
CY1119914T1 CY20181100180T CY181100180T CY1119914T1 CY 1119914 T1 CY1119914 T1 CY 1119914T1 CY 20181100180 T CY20181100180 T CY 20181100180T CY 181100180 T CY181100180 T CY 181100180T CY 1119914 T1 CY1119914 T1 CY 1119914T1
Authority
CY
Cyprus
Prior art keywords
human ngf
ngf antibody
antibody
amino acid
acid sequence
Prior art date
Application number
CY20181100180T
Other languages
English (en)
Inventor
Masazumi Kamohara
Hirotsugu Tanaka
Yukari KOYA
Jun Takasaki
Atsuo YONEZAWA
Eiji Yoshimi
Original Assignee
Astellas Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc. filed Critical Astellas Pharma Inc.
Publication of CY1119914T1 publication Critical patent/CY1119914T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Να παρέχεται αντι-ανθρώπινου NGF αντίσωμα ή θραύσμα σύνδεσης αντιγόνου αυτού που είναι εξαιρετικό στην ασφάλεια με μείωση του κινδύνου παρενεργειών όπως αποτελεσμάτων επί εμβρύου και σχηματισμού θρόμβου, ενώ διατηρεί εντόνως εξουδετερωτική δραστικότητα και να παρέχονται μέσα για αποτροπή ή θεραπεία διαφόρων ασθενειών στις οποίες ενέχεται ανθρώπινος NGF στη δημιουργία παθολογικών καταστάσεων, με χρήση του αντισώματος ή του θραύσματος σύνδεσης αντιγόνου αυτού. [Μέσα για Επίλυση] Ένα αντι-ανθρώπινου NGF αντισώματος Fab' θραύσμα που περιλαμβάνει μεταβλητή περιοχή βαριάς αλύσου που συνίσταται από αλληλουχία αμινοξέος που δείχνεται από τη SEQ ID ΝΟ:6 κα μεταβλητή περιοχή ελαφρός αλύσου που συνίσταται από αλληλουχία αμινοξέος π. δείχνεται με SEQ ID ΝΟ:4.
CY20181100180T 2011-08-11 2018-02-14 Νεο αντι-ανθρωπινο ngf αντισωμα CY1119914T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011176209 2011-08-11
JP2011269215 2011-12-08
PCT/JP2012/070433 WO2013022083A1 (ja) 2011-08-11 2012-08-10 新規抗ヒトｎｇｆ抗体

Publications (1)

Publication Number Publication Date
CY1119914T1 true CY1119914T1 (el) 2018-06-27

Family

ID=47668585

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100180T CY1119914T1 (el) 2011-08-11 2018-02-14 Νεο αντι-ανθρωπινο ngf αντισωμα

Country Status (28)

Country Link
US (2) US8986952B2 (el)
EP (1) EP2743348B1 (el)
JP (1) JP5376095B2 (el)
KR (1) KR101999867B1 (el)
CN (1) CN103748222B (el)
AR (1) AR087506A1 (el)
AU (1) AU2012293161B2 (el)
BR (1) BR112014002576B1 (el)
CA (1) CA2841181C (el)
CY (1) CY1119914T1 (el)
DK (1) DK2743348T3 (el)
EA (1) EA024292B1 (el)
ES (1) ES2663968T3 (el)
HR (1) HRP20180155T1 (el)
HU (1) HUE036079T2 (el)
IL (1) IL230797A (el)
IN (1) IN2014CN00614A (el)
LT (1) LT2743348T (el)
ME (1) ME02944B (el)
MX (1) MX351273B (el)
NO (1) NO2743348T3 (el)
PL (1) PL2743348T3 (el)
PT (1) PT2743348T (el)
RS (1) RS56876B1 (el)
SI (1) SI2743348T1 (el)
TW (1) TWI554519B (el)
WO (1) WO2013022083A1 (el)
ZA (1) ZA201400741B (el)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
WO2012075340A2 (en) 2010-12-01 2012-06-07 Alderbio Holdings Llc Anti-ngf compositions and use thereof
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
JP6135161B2 (ja) * 2013-02-08 2017-05-31 アステラス製薬株式会社 新規抗ヒトｎｇｆ抗体
US9127055B2 (en) 2013-02-08 2015-09-08 Astellas Pharma Inc. Method of treating pain with anti-human NGF antibody
CN107614683B (zh) * 2015-05-22 2020-12-22 安斯泰来制药株式会社 新型抗人NGF抗体Fab片段
CA3018473A1 (en) 2016-03-25 2017-09-28 Astellas Pharma Inc. Pharmaceutical composition comprising pegylated fab' fragment of anti-human ngf antibody
CN114751982B (zh) * 2017-12-15 2023-06-23 安源医药科技（上海）有限公司 抗人ngf抗体及其制备方法和用途
EP3795176A4 (en) 2018-05-15 2022-01-12 Astellas Pharma Inc. PHARMACEUTICAL COMPOSITION FOR SUPPRESSION OF ATRIAL FIBRILLATION WITH ANTI-HUMAN NGF ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AS AN ACTIVE SUBSTANCE

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US6114143A (en) * 1993-03-11 2000-09-05 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Anti-HIV monoclonal antibody
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CN101653604A (zh) 2001-05-30 2010-02-24 基因技术股份有限公司 抗ngf抗体用于治疗各种疾病
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
PT2270048E (pt) 2002-12-24 2016-02-10 Rinat Neuroscience Corp Anticorpos anti-ngf e métodos de utilização dos mesmos
EA013614B1 (ru) 2003-07-15 2010-06-30 Амджен Инк. Изолированное антитело к фактору роста нервов (ngf) и способы его применения
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
CA2595800C (en) 2005-01-24 2014-07-08 Cambridge Antibody Technology Limited. Specific binding members for ngf
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
CA2695997C (en) 2007-08-10 2016-11-22 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human nerve growth factor
WO2009054468A1 (ja) 2007-10-24 2009-04-30 Astellas Pharma Inc. アゾールカルボキサミド化合物又はその塩
PL2448970T3 (pl) 2009-05-04 2014-12-31 Abbvie Res B V Przeciwciało przeciwko czynnikowi wzrostu nerwów (NGF) ze zwiększoną stabilnością in vivo

Also Published As

Publication number Publication date
US20140155582A1 (en) 2014-06-05
DK2743348T3 (en) 2018-02-26
TW201319086A (zh) 2013-05-16
BR112014002576A2 (pt) 2021-01-12
TWI554519B (zh) 2016-10-21
ES2663968T3 (es) 2018-04-17
SI2743348T1 (en) 2018-04-30
AU2012293161A1 (en) 2014-02-06
WO2013022083A1 (ja) 2013-02-14
AR087506A1 (es) 2014-03-26
EA201490433A1 (ru) 2014-05-30
CN103748222A (zh) 2014-04-23
JPWO2013022083A1 (ja) 2015-03-05
EP2743348A1 (en) 2014-06-18
CA2841181A1 (en) 2013-02-14
NO2743348T3 (el) 2018-06-09
EA024292B1 (ru) 2016-09-30
RS56876B1 (sr) 2018-04-30
US20150218265A1 (en) 2015-08-06
US8986952B2 (en) 2015-03-24
CN103748222B (zh) 2015-07-22
LT2743348T (lt) 2018-05-10
HRP20180155T1 (hr) 2018-03-23
EP2743348A4 (en) 2015-04-29
KR101999867B1 (ko) 2019-07-12
BR112014002576B1 (pt) 2022-08-23
ZA201400741B (en) 2014-11-26
IN2014CN00614A (el) 2015-04-03
IL230797A (en) 2017-06-29
MX351273B (es) 2017-10-06
IL230797A0 (en) 2014-03-31
PT2743348T (pt) 2018-02-23
EP2743348B1 (en) 2018-01-10
MX2014001627A (es) 2014-05-28
PL2743348T3 (pl) 2018-04-30
ME02944B (me) 2018-04-20
AU2012293161B2 (en) 2017-04-27
JP5376095B2 (ja) 2013-12-25
CA2841181C (en) 2022-01-25
HUE036079T2 (hu) 2018-06-28
KR20140047116A (ko) 2014-04-21

Similar Documents

Publication Publication Date Title
CY1119914T1 (el) Νεο αντι-ανθρωπινο ngf αντισωμα
CY1121900T1 (el) Ανθρωποποιημενο αντισωμα αντι καλλικρεϊνης-2
CY1124435T1 (el) Νουκλεικα οξεα που κωδικοποιουν ανθρωπινα αντισωματα σε sialyl-lewis α
NZ706377A (en) Il-6 antagonists and uses thereof
CY1119994T1 (el) Συνθεσεις και μεθοδοι για αυξηση της μυϊκης μαζας και της μυϊκης δυναμης ανταγωνιζοντας ειδικα ton gdf8 και/ή την ακτιβινη α
MX2021008888A (es) Anticuerpos anti-tau humanizados.
PE20180604A1 (es) Anticuerpos pd-l1 (que se unen al ligando 1 de muerte celular programada 1 humana)
NZ594682A (en) Fully human antibodies specific to cadm1
UA116873C2 (uk) Антитіло, яке зв'язується з ox40
CO2018002265A2 (es) Anticuerpos anti-cd19 humano humanizados
NZ626269A (en) Anti-phf-tau antibodies and their uses
CO6620013A2 (es) Anticuerpos hacia gdf8 humano
PE20131403A1 (es) Anticuerpos anti-ox40 y metodos de uso de los mismos
EA201070888A1 (ru) Антитела и их производные
PE20141659A1 (es) Dominios variables singulares anti-vgf fusionados con dominios de fc
BR112012021327B8 (pt) anticorpo monoclonal anti-her2 humanizado, método de preparação e uso do mesmo.
EA201591191A1 (ru) Антитела против ntb-a и связанные с ними композиции и способы
FI3653644T3 (fi) Monoklonaalisia vasta-aineita kasvu- ja erilaistumistekijä 15:tä (gdf-15) vastaan sekä niiden käyttöjä syöpään liittyvän kakeksian ja syövän hoitoon
PE20142322A1 (es) Moleculas de anticuerpo anti-gcc y uso de las mismas para probar la susceptibilidad a la terapia dirigida a gcc
UY36942A (es) Proteínas de unión a antígeno que activan el receptor de leptina
EA201301107A1 (ru) Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
EA201492163A1 (ru) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К TrkA, СОДЕРЖАЩИЕ АМИНОКИСЛОТНЫЕ ЗАМЕНЫ
AR098663A1 (es) Anticuerpos multifuncionales que se unen a egfr y met
PH12017500094A1 (en) Novel anti-human tie-2 antibody
ZA202205288B (en) Humanized antibody and method for using the same